{"created":"2023-05-15T14:51:38.180466+00:00","id":70586,"links":{},"metadata":{"_buckets":{"deposit":"9d147e54-7763-4fe3-ac65-c6f5694de3d9"},"_deposit":{"created_by":1,"id":"70586","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"70586"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00070586","sets":["10:28"]},"author_link":["693258","693260","693261","693259","693256","693257"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2011-10-19","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Aim: The aim of the clinical study is to investigate whether PET imaging with a hypoxia tracer [18F]fluoroazomycin arabinoside (FAZA) can discriminate between radioresistant and radiosensitive cancers in histologically-proven primary lung cancer patients planned for radiotherapy. Here shown are the initial results on the [18F]FAZA uptake to the primary lesions.\nMaterials & Methods: Eighteen primary lung cancer patients were enrolled (63 +- 9 y/o, male: female = 11: 7, adenocarcinomas: squamous cell carcinomas: large cell carcinomas = 9: 5: 4, clinical stage IIIA: IIIB: IV = 7: 7: 4). [18F]FAZA-PET images were obtained 2 hours after the tracer injection (370 MBq). The standardized uptake values (SUV), the tumor-to-contralateral normal lung (T/N) ratio, the tumor-to-blood measured in the left ventricle (T/Bl) ratio, and the tumor-to-buck muscles (T/M) ratio were calculated as the semiquantitative parameters for [18F]FAZA uptakes to the primary lesions under the guidance of concomitant CT images. The SUV of [18F]Fluorodeoxylucose (FDG) was also compared with these parameters.\nResults: There was no statistical difference in the maximum tumor diameter or in the SUV of [18F]FDG between genders, among histological types, or among clinical stages. The T/N ratio of [18F]FAZA was significantly higher in patients with large cell carcinomas than those with adenocarcinomas (5.0 +- 1.9 vs 2.5 +- 0.9, p < 0.0001). The T/Bl ratio of [18F]FAZA was significantly correlated with the maximum tumor diameter (R2 = 0.670, p < 0.0001) and with the SUV of [18F]FDG (R2 = 0.507, p < 0.0001), as well as with the SUV of [18F]FAZA (R2 = 0.748, p < 0.0001). The T/M ratio, however, seemed inappropriate as the parameter in lung cancer, since there was a gender difference in the SUV of [18F]FAZA to the buck muscles themselves (male 1.45 +- 0.12 vs female 1.26 +- 0.19, p = 0.02).\nConclusion: Histological difference was found in a parameter of [18F]FAZA uptake to the primary lesions in the lung cancer patients. In addition, reasonable relationships with the tumor size and with the tumor [18F]FDG uptake was found in another parameter of the [18F]FAZA uptake. The best parameter of the [18F]FAZA uptake for predicting the resistance to radiotherapy will be determined through following up the therapeutic outcome of these patients. (364 words)","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"EANM'11 - Annual Congress of the European Association of Nuclear Medicine","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Inubushi, Masayuki"}],"nameIdentifiers":[{"nameIdentifier":"693256","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Koizumi, Mitsuru"}],"nameIdentifiers":[{"nameIdentifier":"693257","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Saga, Tsuneo"}],"nameIdentifiers":[{"nameIdentifier":"693258","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"犬伏 正幸","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"693259","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"小泉 満","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"693260","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"佐賀 恒夫","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"693261","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"Initial Report on [18F]FAZA-PET/CT Clinical Study in Lung Cancer","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Initial Report on [18F]FAZA-PET/CT Clinical Study in Lung Cancer"}]},"item_type_id":"10005","owner":"1","path":["28"],"pubdate":{"attribute_name":"公開日","attribute_value":"2011-10-26"},"publish_date":"2011-10-26","publish_status":"0","recid":"70586","relation_version_is_last":true,"title":["Initial Report on [18F]FAZA-PET/CT Clinical Study in Lung Cancer"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T20:01:12.542308+00:00"}